Drug intelligence / Profile preview

JS010

Development stage: Phase 1
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

JS010 is a recombinant humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody injection developed by Shanghai Junshi Biosciences. It is primarily being developed for the preventive treatment of migraine in adults. JS010 works by binding with high affinity to human α-CGRP and β-CGRP proteins, blocking their combination with receptors, thereby inhibiting the intracellular cAMP signaling pathway. Pre-clinical studies have shown that JS010 has a significant inhibitory effect on vasodilation, which plays a role in migraine prevention.

Targets

CGRP (Calcitonin gene-related peptide)β-CGRP (Beta-calcitonin gene-related peptide)

Beyond the preview

Go deeper on JS010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS010.

Explore the full profile